Interstitial infusion of carmustine in the rat brain stem with systemic administration of O6-benzylguanine

Journal of Neuro-Oncology

Volumn 67, Issue 3, 2004, Pages 319-326

  Souweidane, Mark M ^a   Occhiogrosso, Giuseppe ^a   Mark, Erika B ^a   Edgar, Mark A ^a   Dunkel, Ira J ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BCNU; Brain stem glioma; Carmustine; Interstitial infusion; Pontine glioma

Indexed keywords

6 O BENZYLGUANINE; CARMUSTINE; GLUCOSE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GUANINE; O(6) BENZYLGUANINE; O(6)-BENZYLGUANINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BLOOD ANALYSIS; BRAIN INJURY; BRAIN STEM; CANNULATION; CELL COUNT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG INDICATION; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; GLIOMA; HISTOPATHOLOGY; IMMUNE RESPONSE; INTERSTITIUM; MACROPHAGE; MALE; NEUROLOGIC EXAMINATION; NEUTROPHIL; NONHUMAN; PONS; PONS ANGLE TUMOR; POSTOPERATIVE PERIOD; RAT; STEREOTAXIC SURGERY; SYSTEMIC THERAPY; TOXICITY TESTING; ANIMAL; COMPARATIVE STUDY; DRUG EFFECT; INFUSION PUMP; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN STEM; CARMUSTINE; GUANINE; INFUSION PUMPS; INJECTIONS, INTRAPERITONEAL; MACROPHAGES; MALE; NEUTROPHILS; RATS; RATS, SPRAGUE-DAWLEY; STEREOTAXIC TECHNIQUES;

EID: 2942735187     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NEON.0000024242.59770.7a     Document Type: Article

References (46)

1. Cohen ME, Duffner PK: Brain stem tumors. Brain Tumors in Children: Principles of Diagnosis and Treatment, 2nd edn. Raven Press, Ltd, New York, 1994, pp. 241-262.
2. Albright AL, Guthkelch N, Packer RJ, Price RA, Rourke LB: Prognostic factors in pediatric brain-stem gliomas. J Neurosurg 65: 751-755, 1986
3. Kaplan AM, Albright AL, Zimmerman RA, Rorke LB, Li H, Boyett JM, Finlay JL, Wara WM, Packer RJ: Brainstem gliomas in children: A Children's Cancer Group review of 119 cases. Pediatr Neurosurg 24: 185-192, 1996
4. Sanford RA, Freeman CR, Burger P, Cohen ME: Prognostic crite.ria for experimental protocols in pediatric brainstem gliomas. Surg Neurol 30: 276-280, 1988
5. Sandberg DI, Edgar MA, Souweidane MM: Convection-enhanced delivery into the rat brain stem. J Neurosurg 96: 885-891, 2002
6. Sandberg DI, Edgar MA, Souweidane MM: Effect of hyper-osmolar mannitol on convection-enhanced delivery into the rat brain stem. J Neuro-Oncol 58: 187-192, 2002
7. Occhiogrosso G, Edgar MA, Sandberg DI, Souweidane MM: Prolonged convection enhanced delivery into the rat brain stem. Neurosurgery 52: 388-393, 2003
8. Lonser RR, Walbridge S, Garmestani K, Butman JA, Walters HA, Vortmeyer AO, Morrison PF, Brechbiel MW, Oldfield E: Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg 97: 905-913, 2002
9. Carson BS, Tyler B, Sukay L, Raychaudhuri R, DiMeco F, Clatterbuck RE, Olivi A, Guarnicri M: New approach to tumor therapy for inoperable areas of the brain: chronic intraparenchymal drug delivery. J Neuro-Oncol 60: 151-158, 2002
10. Wu Q, Tyler B, Sukay L, Rhines L, DiMeco F, Clatterbuck RE, Guarnicri M, Carson BS Sr: Experimental rodent models of brainstem tumors. Vet Pathol 39: 293-299, 2002
11. Yachnis A: Neuropathology of pediatric brain tumors. Sem Pediatr Neurol 4: 282-291, 2000
12. Fisher PG, Breiter SN, Carson BS, Wharam MD, Williams JA, Weingart JD, Foer DR, Goldthwaite PT, Tihan T, Burger P: A clinicopathologic reappraisal of brain stem tumor classification. Cancer 89: 1569-1576, 2000
13. Chuba PJ, Zamarano L, Hamre M, Bhambhani K, Canady A, Guys MB, Matter A, Portillo G, Chung-bin S, Fontanesi J: Permanent I-125 brain stem implants in children. Childs Nerv Syst 14: 570-577, 1998
14. Mandell LR, Kadota R, Freeman C, Douglass EC, Fontanesi J, Cohen ME, Kovnar E, Burger P, Sanford RA, Kepner J, Friedman H, Kun LE: There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys 43: 959-964, 1999
15. Packer RJ: Alternative therapies for children with brain stem gliomas: immunotherapy and gene therapy. Pediatr Neurosurg 24: 217-222, 1996
16. Dunkel IJ, O'Malley B, Finlay JL: Is there a role for high-dose chemotherapy with stem cell rescue for brain stem tumors of childhood? Pediatr Neurosurg 24: 263-266, 1996
17. Allen JC, Siffert J: Contemporary chemotherapy issues for children with brainstem gliomas. Pediatr Neurosurg 24: 98-102, 1996
18. Chamberlain MC: Recurrent brainstem gliomas treated with oral VP-16. J Neuro-Oncol 15: 133-139, 1993
19. Dunkel IJ, Garvin JH, Jr, Goldman S, Ettinger LJ, Kaplan AM, Cairo M, Li H, Boyett JM, Finlay JL: High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. Children's Cancer Group. J Neuro-Oncol 37: 67-73, 1998
20. Fulton DS, Levin VA, Wara WM, Edwards MS, Wilson CB: Chemotherapy for pediatric brain-stem tumors. J Neurosurg 54: 721-725, 1981
21. Jenkin RD, Boesel C, Ertel I, Evenas A, Hittle R, Ortega J, Sposto R, Wara W, Wilson C, Anderson J, Leidin S, Hammond GD: Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone: a report of the Children's Cancer Study Group. J Neurosurg 66: 227-233, 1987
22. Jennings MT, Freeman ML, Murray MJ: Strategies in the treatment of diffuse pontine gliomas: the therapeutic role of hyperfractionated radiotherapy and chemotherapy. J Neuro-Oncol 28: 207-222, 1996
23. Kedar A, Maria BL, Graham-Pole J, Ringdahl DM, Quisling RG, Mickle JP, Mendenhall NP, Marcus RB Jr, Gross S: High-dose chemotherapy with marrow reinfusion and hyperfractionated irradiation for children with high-risk brain tumors. Med Pediatr Oncol 23: 428-436, 1994
24. Kretchner CS, Turbell NJ, Barnes PD, Krischer JP, Burger PC, Kun L: Pre-irradiation chemotherapy and hyperfractionated radiation therapy 66Gy for children with brainstem tumors. A phase II study of the Pediatric Oncology Group, Protocol 8833. Cancer 72: 1404-1413, 1994
25. Packer RJ, Nicholson HS, Vezina LG, Johnson DL: Brainstem gliomas. Pediatr Neuro-Oncol 4: 863-879, 1992
26. Walter AW, Gajjar A, Ochs JS, Langston JW, Sanford RA, Kun LE, Heideman R: Carboplatin and etopiside with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: a phase I/II study. Med Pediatr Oncol 30: 28-33, 1998
27. Groothuis DR: The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro-Oncology 2: 45-59, 2000
28. Morrison PF, Laske DW, Bobo H, Oldfield EH, Dedrick RL, High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol 266: R292-R305, 1994
29. Chen MY, Lonser RR, Morrison PF, Governale LS, Oldfield EH: Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 90: 315-320, 1999
30. Kroll RA, Pagel MA, Muldoon LL, Roman, Goldstein S, Neuwelt EA: Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery 38: 746-754, 1996
31. 14C-sucrose delivery to the brain by intravenous, intraventricular, and convection-enhanced intracerebral infusion. J Neurosurg 90: 321-331, 1999
32. Groothuis DR, Benalcazar H, Allen CV, Wise RM, Dills C, Dobrescu C, Rothholz V, Levy RM: Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration. Brain Res 856: 281-290, 2000
33. Brem H, Ewend MG, Piantadosi S, Greenhoot J, Burger BC, Sisti M: The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of new diagnosed malignant: phase I trial. J Neuro-Oncol 26: 111-123, 1995
34. Boiardi AS, Pozzi A, Fariselli L, Broggi G, Salmaggi A: Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: improved survival in sequential studies. J Neuro-Oncol 41: 151-157, 1999
35. Bradford R, Darling JL, Thomas DG: The chemotherapeutic response of a murine (VM) model of human glioma. Br J Cancer 61: 46-50, 1990
36. Yang MB, Tamargo RJ, Brem H: Controlled delivery of 1,3-bis(2-chloroethyl)-1-nitrosourea from ethylene-vinyl acetate copolymer. Cancer Res 49: 5103-5107, 1989
37. Schold CS, Bigner DD: Treatment of five subcutaneous human glioma tumor cell lines in athymic mice with carmustine, procarbazine and mithramycin. Cancer Treat Rep 67: 811-819, 1983
38. Schold SC, Kuhn JG, Chang SM, Bosik ME, Robins HI, Mehta MP, Spence AM, Fulton D, Fink KL, Prados MD: A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study. Neuro-oncol 2: 34-39, 2000
39. Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, Mealey J Jr, Odom GL, Paoletti P, Ransohoff J II, Robertson JT, Selker RG, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA: Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67: 121-132, 1983
40. Kornblith PL, Walter M: Chemotherapy for malignant gliomas. J Neurosurg 68: 1-17, 1988
41. Kokkinakis DM, Moschel RC, Pegg AE, Schold SC: Potentiation of BCNU antitumor efficacy by 9-substituted O6 benzylguanines. Effect of metabolism. Cancer Chemother Pharmacol 45: 69-77, 2000
42. Rhines L, Sampath P, Dolan ME, Tyler BM, Brem H, Weingart JD: O6 Benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intercranial rat glioma. Cancer Res 60: 6307-6310, 2000
43. Chen Z, Pan J, Huang Q, Sun ZF, Zhou LY, Wang AD: Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter. J Neuro-Oncol 51: 19-24, 2001
44. Friedman HS, Kokkinakis DM, Pluda J, Friedman AH, Cokgor I, Haglund MM, Ashley DM, Rich J, Dolan ME, Pegg AE, Moschel RC, McLendon RE, Kerby T, Herndon JE, Bigner DD, Schold SC Jr: Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 16: 3570-3575, 1998
45. Friedman H, Pluda J, Quinn JA, Ewesuedo RB, Long L, Friedman AH, Cokgor I, Colvin OM, Haglund MM, Ashley DM, Rich JS, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Stewart ES, Tourt-Uhlig S, Garcia-Turner M, Herndon JE II, Bigner DD, Dolan ME: Phase I trial of carmustine of O6 benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 18: 3522-3528, 2000
46. Quinn J, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon JE II, Bigner DD, Friedman HS: Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 20: 2277-2283, 2002